Labiotech.eu

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Mar 2015

Vitic database, the new must-have tool

The latest version of the Vitic Intermediates database, chemical database and information management system, has been released by Lhasa Limited, a leading global supplier of knowledge based software and associated databases. Initiated in 2006, Vitic Intermediates is a cross industry data sharing consortium created and co-ordinated by Lhasa Limited, through the Vitic Nexus platform, supported by […]

March 11, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 10 Mar 2015

The Promising Company OSE Pharma launches an IPO

Created in 2012 by Emile Loria and Dominique Costantini, OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. The company announced the launch of its Initial Public Offering (IPO) on Euronext’s regulated […]

March 10, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 10 Mar 2015

350th anniversary of Philosophical Transactions, the first scientific journal

The world’s oldest continuously published journal, Philosophical Transactions of the Royal Society of London (RSL), celebrates its 350th anniversary on 6 March 2015. Academic journals are the cornerstone of science research. They serve as showcases, forums where researchers present their discoveries to the scientific community so they can be scrutinized, criticized and confirmed or rejected. […]

March 10, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 10 Mar 2015

Live from Bio-Europe 2015: The product development challenges in the gene therapy field

Gene Therapy is really the hot topic right now in the field of Biotech especially with technologies such as CRISPR and CAR-T therapies. The value of such companies are skyrocketing and many see the field as the next potential blockbuster therapies. Gene therapy has clearly a huge potential but also lot of challenges, let’s go through […]

March 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 9 Mar 2015

MorphoSys and Emergent BioSolutions Initiate Phase I

MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). A few months ago, we talked about the beginning of the collaboration between MorphoSys and Emergent BioSolutions. Now, the fruit of their combined work, an […]

March 9, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 9 Mar 2015

An Inside Look: Zurich Life Science Day 2015

Over 600 people from all stretches of the globe gathered on February 12 for the Zurich Life Science Day at the University of Zurich. My first impression walking there was that the campus (both the Irchel campus it was held at and main campus I mistakenly went to first) were beautiful. I had low expectations […]

March 9, 2015 - 7 minutesmins - By Joachim Eeckhout

News and Trends 7 Mar 2015

New insights into drought tolerance in plants

Spanish researchers found a new family of proteins that controls plant resistance to drought. The work will allow the design of crop plants with improved properties over this type of stress. Two teams of the Spanish National Research Council (CSIC in Spanish) have identified and characterized a new protein family that directly controls the drought […]

March 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Novartis achieves the First Biosimilar approval in US

The Novartis company Sandoz has become the first company with a biosimilar approved by the US Food and Drug Administration (FDA) after today’s approval of Zarxio, a treatment for neutropenia. Sandoz is the first company to receive the approval of a biosimilar in the US through the new FDA biosimilars pathway established under Biologics Price […]

March 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Petunica circadia, where Art and Biotechnology meet

A changing-color flower that goes from blue to red and viceversa? It may sound like science fiction, but it’s purely biotechnology. A simple petunia to make a statement: gene engineering is not something to be afraid of. Biotechnology has so many applications that go from nourishing the increasing world population to growing beautiful flowers to […]

March 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Global Bioenergies Produces its First “Second Generation” Isobutene

We already presented Global Bioenergies in our article “Is France leading the European Synthetic Biology-based Biofuel field?”, but as a reminder the company is developing a process to convert renewable resources into hydrocarbons (more specifically isobutene, a building blocks that can be converted into fuels, plastics, organic glass and elastomers) through fermentation. Global Bioenergies annouced having […]

March 6, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Mar 2015

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small […]

March 5, 2015 - 5 minutesmins - By Cédric Brock

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Vitic database, the new must-have tool

The Promising Company OSE Pharma launches an IPO

350th anniversary of Philosophical Transactions, the first scientific journal

Live from Bio-Europe 2015: The product development challenges in the gene therapy field

MorphoSys and Emergent BioSolutions Initiate Phase I

An Inside Look: Zurich Life Science Day 2015

New insights into drought tolerance in plants

Novartis achieves the First Biosimilar approval in US

Petunica circadia, where Art and Biotechnology meet

Global Bioenergies Produces its First “Second Generation” Isobutene

Novartis announces completion of transactions with GSK

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!